HK1048941B - 具有治療學有用性質的吲哚基-3-乙醛酸衍生物 - Google Patents

具有治療學有用性質的吲哚基-3-乙醛酸衍生物

Info

Publication number
HK1048941B
HK1048941B HK03101178.9A HK03101178A HK1048941B HK 1048941 B HK1048941 B HK 1048941B HK 03101178 A HK03101178 A HK 03101178A HK 1048941 B HK1048941 B HK 1048941B
Authority
HK
Hong Kong
Prior art keywords
indolyl
acid derivatives
glyoxylic acid
therapeutically valuable
valuable properties
Prior art date
Application number
HK03101178.9A
Other languages
English (en)
Other versions
HK1048941A1 (en
Inventor
B‧尼克爾
T‧克倫尼爾
G‧巴徹爾
T‧拜克爾斯
P‧艾米格
J‧恩格爾
E‧布魯尼爾
G‧卡姆
K‧皮特斯
Original Assignee
巴克斯特保健股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19946301A external-priority patent/DE19946301A1/de
Application filed by 巴克斯特保健股份有限公司 filed Critical 巴克斯特保健股份有限公司
Publication of HK1048941A1 publication Critical patent/HK1048941A1/xx
Publication of HK1048941B publication Critical patent/HK1048941B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK03101178.9A 1999-09-28 2003-02-18 具有治療學有用性質的吲哚基-3-乙醛酸衍生物 HK1048941B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19946301A DE19946301A1 (de) 1998-04-02 1999-09-28 Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
PCT/EP2000/009390 WO2001022954A2 (de) 1999-09-28 2000-09-26 Indolyl-3-glyoxylsäurederivate als antitumormittel

Publications (2)

Publication Number Publication Date
HK1048941A1 HK1048941A1 (en) 2003-04-25
HK1048941B true HK1048941B (zh) 2007-09-21

Family

ID=7923485

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03101178.9A HK1048941B (zh) 1999-09-28 2003-02-18 具有治療學有用性質的吲哚基-3-乙醛酸衍生物

Country Status (32)

Country Link
EP (1) EP1218006B1 (zh)
JP (1) JP2003510274A (zh)
KR (1) KR100759242B1 (zh)
CN (1) CN1301712C (zh)
AR (1) AR025885A1 (zh)
AT (1) ATE459356T1 (zh)
AU (1) AU783436B2 (zh)
BG (1) BG106639A (zh)
BR (1) BR0014378A (zh)
CA (1) CA2386069C (zh)
CZ (1) CZ303246B6 (zh)
DE (1) DE50015879D1 (zh)
DZ (1) DZ3196A1 (zh)
EE (1) EE200200169A (zh)
ES (1) ES2342042T3 (zh)
GE (1) GEP20043250B (zh)
HK (1) HK1048941B (zh)
HR (1) HRP20020369A2 (zh)
HU (1) HUP0202788A3 (zh)
IL (2) IL148670A0 (zh)
IS (1) IS6319A (zh)
MX (1) MXPA02002824A (zh)
NO (1) NO322614B1 (zh)
NZ (1) NZ517988A (zh)
PL (1) PL199576B1 (zh)
RS (1) RS51302B (zh)
RU (1) RU2282444C2 (zh)
SK (1) SK287533B6 (zh)
TW (1) TWI269654B (zh)
UA (1) UA75872C2 (zh)
WO (1) WO2001022954A2 (zh)
ZA (1) ZA200202556B (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
EP1595878A1 (de) * 2004-05-15 2005-11-16 Zentaris GmbH Indolderivate mit Apoptose induzierender Wirkung
EP1484329A1 (de) * 2003-06-06 2004-12-08 Zentaris GmbH Indolderivate mit Apoptose induzierender Wirkung
KR101132599B1 (ko) * 2003-06-05 2012-06-21 아에테르나 젠타리스 게엠베하 아폽토시스 유도 효과를 갖는 인돌 유도체
US20050124623A1 (en) 2003-11-26 2005-06-09 Bender John A. Diazaindole-dicarbonyl-piperazinyl antiviral agents
CN106434833A (zh) * 2004-05-23 2017-02-22 杰勒德·M·豪斯 Theramutein调节剂
CA2587276A1 (en) * 2004-11-08 2006-05-18 Baxter International Inc. Nanoparticulate compositions of tubulin inhibitor compounds
US20060100432A1 (en) 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US9040558B2 (en) 2004-12-31 2015-05-26 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US7851476B2 (en) 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
EP2091532A1 (en) * 2006-11-28 2009-08-26 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
CA2845284C (en) 2011-08-18 2018-03-06 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors
EP2760864B1 (en) 2011-09-27 2018-01-24 Dr. Reddy's Laboratories Ltd. 5-BENZYLAMINOMETHYL-6-AMINOPYRAZOLO[3,4-b]PYRIDINE DERIVATIVES AS CHOLESTERYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS USEFUL FOR THE TREATMENT OF ATHEROSCLEROSIS
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
EP2972394A4 (en) 2013-03-15 2016-11-02 Sloan Kettering Inst Cancer HSP90 TARGETING CARDIAC IMAGING AND TREATMENT THEREOF
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CN109111501B (zh) * 2017-06-23 2022-04-22 首都医科大学 脂肪氨基酸修饰的吲哚乙醇衍生物, 其合成，活性和应用
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
CA2126217A1 (en) * 1992-10-20 1994-04-28 Katsuhiro Shibayama Agent for suppressing infiltration of eosinophilis
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
EP0974652A4 (en) 1997-04-08 2000-08-30 Banyu Pharma Co Ltd GENE ASSOCIATED WITH CANCER METASTASE
CN1310706A (zh) * 1998-02-25 2001-08-29 遗传研究所有限公司 磷脂酶抑制剂
KR20010041811A (ko) * 1998-03-12 2001-05-25 온토젠 코포레이션 단백질 티로신 포스파타제의 조절제
DE19814838C2 (de) 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
TR200003130T2 (tr) * 1998-04-28 2001-01-22 Arzneimittelwerk Dresden Gmbh Yeni hidroksiindoller, bunların fosfodiesteraz 4 inhibitörleri olarak kullanımları ve hazırlanmaları için işlemler
JP2000239252A (ja) * 1999-02-16 2000-09-05 Mitsubishi Chemicals Corp インドール誘導体
AU4834200A (en) * 1999-05-10 2000-11-21 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof

Also Published As

Publication number Publication date
IL148670A0 (en) 2002-09-12
EP1218006B1 (de) 2010-03-03
DZ3196A1 (fr) 2001-04-05
GEP20043250B (en) 2004-06-25
IL148670A (en) 2009-09-01
RS51302B (sr) 2010-12-31
HUP0202788A3 (en) 2003-02-28
BG106639A (bg) 2002-12-29
CN1301712C (zh) 2007-02-28
PL199576B1 (pl) 2008-10-31
MXPA02002824A (es) 2003-07-21
CN1376064A (zh) 2002-10-23
TWI269654B (en) 2007-01-01
NO322614B1 (no) 2006-11-06
ES2342042T3 (es) 2010-07-01
DE50015879D1 (de) 2010-04-15
NO20021367L (no) 2002-05-22
CZ20021005A3 (cs) 2004-01-14
AU783436B2 (en) 2005-10-27
SK287533B6 (sk) 2011-01-04
HRP20020369A2 (en) 2004-12-31
BR0014378A (pt) 2003-07-29
CA2386069A1 (en) 2001-04-05
AU7782900A (en) 2001-04-30
EP1218006A2 (de) 2002-07-03
HK1048941A1 (en) 2003-04-25
YU22702A (sh) 2004-12-31
NZ517988A (en) 2004-10-29
WO2001022954A3 (de) 2002-03-28
UA75872C2 (en) 2006-06-15
NO20021367D0 (no) 2002-03-19
IS6319A (is) 2002-03-21
WO2001022954A2 (de) 2001-04-05
CA2386069C (en) 2012-08-14
HUP0202788A2 (hu) 2003-01-28
JP2003510274A (ja) 2003-03-18
EE200200169A (et) 2003-04-15
AR025885A1 (es) 2002-12-18
CZ303246B6 (cs) 2012-06-20
SK4072002A3 (en) 2003-11-04
ZA200202556B (en) 2003-08-27
RU2282444C2 (ru) 2006-08-27
KR20030019295A (ko) 2003-03-06
PL364811A1 (en) 2004-12-13
ATE459356T1 (de) 2010-03-15
KR100759242B1 (ko) 2007-09-18

Similar Documents

Publication Publication Date Title
IL148670A0 (en) Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties
GB9904103D0 (en) Quinoline derivatives
EG23070A (en) Novel propargylether derivatives
PL351686A1 (en) Novel pharmaceutical
IL150337A0 (en) Phenylpiperazinyl derivatives
HRP20000529B1 (en) Novel dihydroxyhexanoic acid derivatives
EG23937A (en) Novel pharmaceutical
HK1047274A1 (zh) 氨基苯甲酸衍生物
HUP0103788A3 (en) Processes for the preparation of 5-hydroxy-3-oxopentanoic acid derivatives
AU1303201A (en) Alkoxyiminoalkanoic acid derivatives
AU6624000A (en) Recrystallization process
HUP0204217A3 (en) Novel a-500359 derivatives
AUPQ365299A0 (en) Anthranilic acid derivatives
GB9909041D0 (en) Novel pharmaceutical
EG23946A (en) Novel pharmaceutical
GB9914583D0 (en) Novel process
AU2690600A (en) 2-mercaptocarboxylic acid derivatives
GB9916187D0 (en) Novel process
GB0017435D0 (en) 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivatives
GB9923934D0 (en) Novel pharmaceutical
GB9915303D0 (en) Novel process
GB9915542D0 (en) Therapeutically useful compounds
GB2355429B (en) Improved structure for manufacture
AUPP812699A0 (en) Direct smelting process
GB9912195D0 (en) Novel pharmaceutical

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140926